Understanding Platelet Transfusion Refractoriness
Characterization of Anti-HLA I Antibodies Involved in Platelet Transfusion Refractoriness: Optimization of the Transfusion Management of Patients With Severe Thrombocytopenia
This study is trying to find out how certain antibodies affect patients with severe low platelet counts who have trouble getting benefits from platelet transfusions, to help doctors manage their treatment better.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Institut de cancérologie Strasbourg Europe Academic / other |
| Locations | 1 site (Strasbourg) |
| Trial ID | NCT05399693 on ClinicalTrials.gov |
What this trial studies
This observational study investigates Platelet Transfusion Refractoriness, a serious complication that can occur after multiple platelet transfusions in patients with severe thrombopenia. It aims to identify the types and quantities of anti-HLA I antibodies present in affected patients to establish predictive and diagnostic criteria. By analyzing these antibodies, the study seeks to improve the management of platelet transfusions in this patient population.
Who should consider this trial
Good fit: Ideal candidates for this study are adult patients with hematopoietic stem cell grafts or acute leukemia who require platelet transfusions.
Not a fit: Patients under guardianship or minors will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better diagnostic tools and treatment strategies for patients experiencing platelet transfusion refractoriness.
How similar studies have performed: While the approach of analyzing anti-HLA I antibodies is promising, it is not widely tested in this specific context, making this study somewhat novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patient with Hematopoietic stem cells graft (autograft or allograft) or with acute leukemia with the indication of platelet transfusion. Exclusion Criteria: * Patient under guardianship * Minor patient
Where this trial is running
Strasbourg
- Institut de cancérologie Strasbourg Europe — Strasbourg, France (Recruiting)
Study contacts
- Principal investigator: Luc FORNECKER — Institut de cancérologie Strasbourg Europe
- Study coordinator: Manon VOEGELIN
- Email: promotion-rc@icans.eu
- Phone: 03 68 33 95 23
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.